U.S. FDA okays expanded use of Medivation prostate cancer drug
September 10, 2014 at 17:21 PM EDT
Sept 10 (Reuters) - U.S. health regulators approved the use of Medivation Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the company said on Wednesday, significantly expanding the potential patient population for the oral medicine.